Connect your AI

Monte Rosa Therapeutics, Inc. GLUE Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

Nurix Therapeutics, Inc.NRIX

3.4×+1.0×

Kymera TherapeuticsKYMR

4.4×+2.2×

ImmunomeIMNM

4.2×+2.3×

Cogent Biosciences, Inc.COGT

10.3×+7.2×

Adaptive BiotechnologiesADPT

9.9×+4.1×

Other financials

Income statement

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=2.5×

Based on the most recent quarter.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s price / book?: Monte Rosa Therapeutics, Inc. (GLUE) reported price / book of 2.5× in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s price / book changed year-over-year?: Monte Rosa Therapeutics, Inc.'s price / book increased by 143.2% year-over-year, from 1× to 2.5×.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s price / book?: Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s price / book has grown at a 12.5% compound annual growth rate (CAGR), from 2.7× to 4.4×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.